van de Donk N, Pawlyn C, Yong KL et al (2021) Multiple myeloma. Lancet 397(10272):410–427

Article  PubMed  Google Scholar 

Cowan AJ, Green DJ, Kwok M et al (2022) Diagnosis and Management of Multiple Myeloma: A Review. JAMA 327(5):464–477

Article  CAS  PubMed  Google Scholar 

Wallington-Beddoe CT, Mynott RL (2021) Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol 14(1):151

Article  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

Zhao Y, Niu D, Ye E et al (2022) Secular Trends in the Burden of Multiple Myeloma From 1990 to 2019 and Its Projection Until 2044 in China. Front Public Health 10:938770

Article  PubMed  PubMed Central  Google Scholar 

Huang J, Chan SC, Lok V et al (2022) The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol 9(9):e670–e677

Article  Google Scholar 

Branagan A, Lei M, Lou U, Raje N (2020) Current Treatment Strategies for Multiple Myeloma. JCO Oncol Pract 16(1):5–14

Article  PubMed  Google Scholar 

Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95(5):548–567

Article  CAS  PubMed  Google Scholar 

Ding K, Jiang W, Jia H, Lei M (2022) Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib. Biomolecules 12(11)

Kozalak G, Butun I, Toyran E, Kosar A (2023) Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies. Pharmaceuticals (Basel) 16(1)

Palumbo A, Chanan-Khan A, Weisel K et al (2016) Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375(8):754–766

Article  CAS  PubMed  Google Scholar 

Xia J, He Y, Meng B et al (2020) NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma. Mol Oncol 14(4):763–778

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao YZ, Sun JY, Chen YX et al (2021) The roles of circRNAs in cancers: Perspectives from molecular functions. Gene 767:145182

Article  CAS  PubMed  Google Scholar 

Chen L, Shan G (2021) CircRNA in cancer: Fundamental mechanism and clinical potential. Cancer Lett 505:49–57

Article  CAS  PubMed  Google Scholar 

Zhao X, Cai Y, Xu J (2019) Circular RNAs: Biogenesis, Mechanism, and Function in Human Cancers. Int J Mol Sci 20(16)

Tang X, Ren H, Guo M et al (2021) Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J 19:910–928

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Lin Q, Song C et al (2020) Circ_0007841 promotes the progression of multiple myeloma through targeting miR-338-3p/BRD4 signaling cascade. Cancer Cell Int 20:383

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Lin Q, Song C et al (2020) Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis. Cell Cycle 19(23):3289–3302

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ludwig H, Miguel JS, Dimopoulos MA et al (2014) International Myeloma Working Group recommendations for global myeloma care. Leukemia 28(5):981–992

Article  CAS  PubMed  Google Scholar 

Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420

Article  PubMed  Google Scholar 

Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 33(26):2863–2869

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao M, Li C, Xiao H et al (2019) hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma. Front Oncol 9:1261

Article  PubMed  PubMed Central  Google Scholar 

Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346

Article  PubMed  Google Scholar 

Huang K, Liu D, Su C (2021) Circ_0007841 accelerates ovarian cancer development through facilitating MEX3C expression by restraining miR-151-3p activity. Aging (Albany NY) 13(8):12058–12066

Article  CAS  PubMed  Google Scholar 

Long F, Li Z, Wei Z, Xie Y (2022) Circular RNA circ_0007841 participates in progression of nonsmall cell lung cancer via miR-199a-5p/SphK2 axis. Anticancer Drugs 33(10):1035–1046

Article  CAS  PubMed  Google Scholar 

Song Y, Hu N, Song X, Yang J (2020) Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2. Technol Cancer Res Treat 19:1533033820928371

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viol Ferreira Lopes MA, Higashi F, Crusoe EQ et al (2022) Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life. Hematol Transfus Cell Ther

Rajkumar SV (2016) Myeloma today: Disease definitions and treatment advances. Am J Hematol 91(1):90–100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonello F, Cani L, D’Agostino M (2022) Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting. Front Oncol 12:830922

Article  PubMed  PubMed Central  Google Scholar 

Zhong L, Hao P, Zhang Q et al (2022) Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM). Elife 11